Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-AAZTA-NI-093 PET/CT in Prostate Cancer
NCT06612580Phase 1Recruiting
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Sep 2024
- Primary completion
- Aug 2025
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68ga-aazta-ni-093 in prostate cancer (PCa), sponsored by The First Hospital of Fujian Medical University. Primary endpoint: Adverse events at 7 days. Started Sep 2024; status: recruiting.
02
Drugs
68ga-aazta-ni-093
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06612580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06612580.